Get started
Atara Biotherapeutics, Inc.Atara Biotherapeutics, Inc.Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ATRA chart


Full chart

ATRA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪70.27 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−25.66 USD
Net income (FY)
‪−276.13 M‬ USD
Revenue (FY)
‪8.57 M‬ USD
Shares float
‪4.23 M‬
Beta (1Y)
1.09

Employees


Employees (FY)
225
Change (1Y)
−109 −32.63%
Revenue / Employee (1Y)
‪38.10 K‬ USD
Net income / Employee (1Y)
‪−1.23 M‬ USD

About Atara Biotherapeutics, Inc.


Sector
Health Technology
CEO
Anhco Nguyen
Headquarters
Thousand Oaks
Website
atarabio.com
Founded
2012
FIGI
BBG005Q3MQY4
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ATRA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ATRA is 13.33 USD — it has increased by 9.26% in the past 24 hours. Watch Atara Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atara Biotherapeutics, Inc. stocks are traded under the ticker ATRA.
ATRA stock has risen by 26.83% compared to the previous week, the month change is a 25.28% rise, over the last year Atara Biotherapeutics, Inc. has showed a 6.64% increase.
We've gathered analysts' opinions on Atara Biotherapeutics, Inc. future price: according to them, ATRA price has a max estimate of 25.00 USD and a min estimate of 10.00 USD. Watch ATRA chart and read a more detailed Atara Biotherapeutics, Inc. stock forecast: see what analysts think of Atara Biotherapeutics, Inc. and suggest that you do with its stocks.
ATRA reached its all-time high on Jul 14, 2015 with the price of 1,639.00 USD, and its all-time low was 4.97 USD and was reached on Nov 13, 2023. View more price dynamics on ATRA chart.
See other stocks reaching their highest and lowest prices.
ATRA stock is 10.12% volatile and has beta coefficient of 1.09. Track Atara Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Atara Biotherapeutics, Inc. there?
Today Atara Biotherapeutics, Inc. has the market capitalization of ‪70.27 M‬, it has increased by 17.87% over the last week.
Yes, you can track Atara Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Atara Biotherapeutics, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
ATRA earnings for the last quarter are −2.93 USD per share, whereas the estimation was −1.89 USD resulting in a −55.23% surprise. The estimated earnings for the next quarter are −1.85 USD per share. See more details about Atara Biotherapeutics, Inc. earnings.
Atara Biotherapeutics, Inc. revenue for the last quarter amounts to ‪40.19 M‬ USD, despite the estimated figure of ‪28.66 M‬ USD. In the next quarter, revenue is expected to reach ‪28.85 M‬ USD.
ATRA net income for the last quarter is ‪−21.91 M‬ USD, while the quarter before that showed ‪−19.05 M‬ USD of net income which accounts for −15.01% change. Track more Atara Biotherapeutics, Inc. financial stats to get the full picture.
No, ATRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 225.00 employees. See our rating of the largest employees — is Atara Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Atara Biotherapeutics, Inc. EBITDA is ‪−114.25 M‬ USD, and current EBITDA margin is ‪−3.08 K‬%. See more stats in Atara Biotherapeutics, Inc. financial statements.
Like other stocks, ATRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atara Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Atara Biotherapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Atara Biotherapeutics, Inc. stock shows the sell signal. See more of Atara Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.